Epidermal growth factor receptor mutations in lung cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Somatic mutations in the epidermal growth factor receptor (EGFR) gene were identified in non-small cell lung cancer (NSCLC) patients in 2004.
• These mutations show a strong correlation with clinical response to gefitinib, an anticancer drug.
• Significant knowledge has since accumulated regarding the oncological properties and clinical relevance of EGFR mutations.

Purpose of the Study:

• To review current knowledge on EGFR mutations in NSCLC.
• To explore the oncological properties and clinical relevance of these mutations.
• To identify new directions for future research based on existing insights.

Main Methods:

• Review of existing literature on EGFR mutations in NSCLC.
• Analysis of mutation distribution within the EGFR kinase domain.
• Correlation of specific mutations (exon 19 deletion, L858R) with gefitinib response.
• Examination of clinicopathological characteristics associated with EGFR mutations.

Main Results:

• Exon 19 deletions and the L858R point mutation account for ~90% of EGFR mutations in NSCLC.
• These specific mutations confer a greater response to gefitinib compared to other EGFR mutations.
• EGFR mutations are prevalent in a subset of NSCLC characterized by female sex, non-smoking status, adenocarcinoma histology, and East Asian ethnicity.
• In Japan, EGFR mutations are found in ~30% of NSCLC and ~40% of resected adenocarcinomas.

Conclusions:

• EGFR mutations are crucial biomarkers in NSCLC, particularly for predicting gefitinib efficacy.
• The specific clinicopathological features associated with these mutations help define a distinct patient subset.
• Further research is needed to address remaining questions and refine our understanding of EGFR mutations in lung cancer and potentially other malignancies.